CSRxP: SENATE JUDICIARY COMMITTEE SHOULD REJECT PHARMA-SUPPORTED POLICIES THAT WOULD UNDERMINE BIPARTISAN PROGRESS ON PATENT ABUSE
Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More
© 2025 CSRXP- All Rights Reserved
CSRxP ENCOURAGES HELP COMMITTEE TO ADVANCE BIPARTISAN SOLUTIONS TO PROMOTE GREATER COMPETITION IN THE PRESCRIPTION DRUG MARKET
Legislation Scheduled for Thursday Markup Would Encourage Adoption of… Read More
CSRxP: BIG PHARMA’S EGREGIOUS GLP-1 PRICES AND ANTI-COMPETITIVE TACTICS UNSUSTAINABLE FOR PATIENTS AND U.S. HEALTH CARE SYSTEM
HELP Committee Hearing an Opportunity to Highlight Staggering Cost… Read More
DOSE OF REALITY: BIG PHARMA’S GLP-1 PRICE-GOUGING UNSUSTAINABLE FOR AMERICAN PATIENTS AND THE U.S. HEALTH SYSTEM
Brand Name Drug Companies Applying Price-Hiking, Patent Abuse Playbook to… Read More
DOSE OF REALITY: BIG PHARMA SETS DRUG PRICES, HIKES DRUG PRICES AND BLOCKS COMPETITION TO KEEP DRUG PRICES HIGH
Lawmakers Should Focus on Holding Big Pharma Accountable for Egregious Pricing… Read More
CSRxP JOINS FELLOW ADVOCATES FOR LOWER DRUG PRICES TO URGE HOUSE JUDICIARY COMMITTEE TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE
Letter Encourages Lawmakers to Advance Bipartisan Solutions to Hold Big Pharma… Read More
CSRxP Launches Seven-Figure Advertising Campaign to Hold Big Pharma Accountable for Egregious Drug Prices, Anti-Competitive Tactics and False Rhetoric
Campaign Will Add Support to Growing Bipartisan Momentum to Crack Down on Big… Read More
They Said It! R Street Institute Expert Explains How Big Pharma Games The Patent System to Keep “Drug Prices Artificially High”
New Report Emphasizes The “Pharmaceutical Industry’s Patent Gamesmanship… Read More
CSRxP: Eli Lilly’s Zepbound Announcement Leaves Prices High for Most Patients, Serves as Powerful Reminder Big Pharma Alone Sets Prices
Lowering Prices for Some Patients at Some Dosages Will Have Limited Impact,… Read More
BIG PHARMA EARNINGS WATCH: ELI LILLY & AMGEN
Price Hikes and Egregious Prices on Blockbuster Drugs Boost Profits… Read More
DOSE OF REALITY: BIG PHARMA’S EGREGIOUS GLP-1, GENE, AND CELL THERAPY PRICES PROJECTED TO INCREASE HEALTH CARE COSTS FOR EMPLOYERS
Analysis Finds GLP-1 Blockbusters and “Multimillion-Dollar Gene Therapies”… Read More
BIG PHARMA EARNINGS WATCH: GSK, PFIZER, MERCK, BRISTOL MYERS SQUIBB
Big Pharma Continues Raking in Expectation-Beating Profits and Revenue Fueled… Read More